» Articles » PMID: 3913771

Drug Interactions with Methotrexate

Overview
Specialty Rheumatology
Date 1985 Dec 1
PMID 3913771
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

General mechanisms of drug interactions are reviewed, as well as the effects of various drugs on the absorption, distribution, protein binding, eliminations and cellular transport of methotrexate. Published studies demonstrate that prior or concomitant administration of other drugs can alter the efficacy and toxicity of methotrexate. Nonabsorbable antibiotics can decrease methotrexate absorption. Nephrotoxic drugs can decrease methotrexate renal clearance. Salicylates and probenecid may decrease the plasma protein binding and renal tubular secretion of methotrexate. However, the clinical significance of many of these drug interactions is not known or has not been substantiated by extensive clinical observations.

Citing Articles

Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate.

Xu Q, Li Z, Ding T, Qiu X, Wu Z Ann Hematol. 2024; 104(1):457-465.

PMID: 39690250 DOI: 10.1007/s00277-024-06146-4.


Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate.

Watts C, Sciasci J, Pauley J, Panetta J, Pei D, Cheng C J Pediatr Hematol Oncol. 2016; 38(6):449-52.

PMID: 27322715 PMC: 4955728. DOI: 10.1097/MPH.0000000000000606.


Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase.

Connors N, Sise M, Nelson L, Hoffman R, Smith S Clin Kidney J. 2015; 7(6):590-2.

PMID: 25859377 PMC: 4389132. DOI: 10.1093/ckj/sfu093.


[Is methotrexate nephrotoxic? Dose-dependency, comorbidities and comedication].

Erdbrugger U, de Groot K Z Rheumatol. 2011; 70(7):549-52.

PMID: 21735288 DOI: 10.1007/s00393-011-0830-6.


Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

Joerger M, Huitema A, Krahenbuhl S, Schellens J, Cerny T, Reni M Br J Cancer. 2010; 102(4):673-7.

PMID: 20125159 PMC: 2837574. DOI: 10.1038/sj.bjc.6605559.